search cancer chemoprev compound deriv plant sourc discov natur product gut-70 isol stem bark calophyllum brasiliens collect brazil significantli inhibit growth leukem cell gut-70 character tricycl coumarin 5-methoxi-2 2-dimethyl-6- 2-methyl-1-oxo-2-butenyl -10-propyl-2h 8h-benzo[1 2-b 4-b']dipyran-8-on inhibit human leukem cell line evalu includ p-glycoprotein overexpress cell line concentr time-depend manner valu 2-5 microm furthermor gut-70 inhibit coloni format normal hematopoiet progenitor microm inhibit prolifer normal human hepatocyt microm gut-70 activ caspas induc apoptosi leukem cell inhibit caspas inhibitor gut-70 induc anti-leukem effect independ p53-p2l wafl/cip1 pathwai increas overal express p27 kip1 p57 kip2 stop cell cycl transit novel anti-cancer drug gut-70 isol stem bark brasiliens induc caspas-mediat p53-independ apoptosi overcom multidrug resist becom potent leukemia therapeut
previous demonstr delta isoform protein kinas pkcdelta importantli involv cell growth inhibit tumor suppress colon cancer cell investig activ mechan action pkcdelta retrovir transduc pkcdelta cdna hct116 human colon cancer cell pkcdelta-overexpress cell hct116/pkcdelta growth-inhibit show mark morpholog chang underw multinucl phenotyp chang characterist mitot catastroph compar control hct116/pkcdelta cell show highli attenu tumorigen profil poor anchorag-independ growth addit transfect cell establish junction-coordin intercellular commun express cell surfac microvilli overexpress colon differenti marker alkalin phosphatas hct116/pkcdelta cell produc kda carboxi-termin catalyt domain parp hct116/pkcdelta cell p21 waf1/cip1 p53 transient upregul pkcdelta transduct p21 null sublin hct116 cell hct116/p21null overexpress pkcdelta affect tumorigen differenti indic p21 essenti antitumorigen activ pkcdelta similarli overexpress pkcdelta caus signific phenotyp chang hct116/e6 cell hct116 sublin p53 protein downregul human papillomaviru gene product conclud overexpress pkcdelta human colon cancer cell induc multipl antineoplast effect depend activ p21 waf1/cip1 p53
inactiv mutat apc thought earli initi event colorect carcinogenesi gain insight relationship diet inactiv apc mutat evalu associ dietari factor occurr mutat dutch case-control studi sporad colorect adenoma 278 case 414 polyp-free control direct-sequenc us screen adenoma mutat mutat cluster region apc truncat mutat detect 161 adenoma red meat consumpt significantli differ relat polyp truncat apc mutat apc polyp compar polyp truncat apc mutat apc polyp highest lowest tertil odd ratio [or] 0.5 confid interv [ci] 0.3-1.0 high intak red meat fat seem increas risk apc polyp apc control red meat 1.0 0.6-1.6 fat 1.1 0.6-1.9 apc control red meat 1.8 1.0-3.1 fat 1.9 1.0-3.7 intak carbohydr invers associ both polyp group most notic apc polyp most evalu dietari factor distinct associ specif apc statu none dietari factor specif associ particular type truncat apc mutat data suggest red meat fat increas risk apc polyp particular wherea carbohydr especi decreas risk apc polyp howev most examin dietari factor appear specif associ occurr truncat apc mutat colorect adenoma seem affect both pathwai equal
tissu inhibitor matrix metalloproteas timp-1 inhibit proteolyt activ matrix metalloproteas herebi prevent cancer invas howev timp-1 possess function inhibit apoptosi induct malign transform stimul cell-growth previous demonstr timp-1 elev blood colorect cancer patient high timp-1 level predict poor prognosi clarifi role timp-1 colorect tumorigenesi express pattern timp-1 benign malign colorect tumor studi case colorect adenocarcinoma timp-1 mrna detect situ hybrid case timp-1 express found fibroblast-like cell locat invas front sporad normal mucosa timp-1 mrna case benign malign epitheli cell vascular cell smooth muscl cell comparison section process timp-1 situ hybrid section immunohistochem stain antibodi timp-1 show good correl timp-1 mrna immunoreact combin timp-1 situ hybrid immunohistochem stain alpha-smooth muscl actin cd68 show timp-1 mrna myofibroblast macrophag timp-1 mrna detect adenomat polyp adenoma area both case associ focal stromal inflamm epitheli-stromal interfac conclus timp-1 express rare event benign human colon tissu highli express myofibroblast associ invad colon cancer cell
purpos power growth-inhibitori action shown n-3 polyunsatur fatti acid colon cancer cell previous describ abil inhibit prolifer colon epitheli cell patient high risk colon cancer work report here investig abil docosahexaeno acid dha potenti antineoplast activ 5-fluorouracil 5-fu p53-wildtyp ls-174 colo 320 p53-mutant ht-29 colo 205 human colon cancer cell method combin dha 5-fu us concentr rang 0.1 1.0 microm much lower current found plasma patient infus drug similarli dha concentr &lt microm us combin 5-fu lower wide us vitro known caus peroxid effect vivo result wherea cell show differ sensit growth-inhibitori action 5-fu dha reduc cell growth independ p53 cellular statu dha synerg 5-fu reduc colon cancer cell growth potenti effect dha attribut enhanc proapoptot effect 5-fu dha markedli increas inhibitori effect 5-fu express antiapoptot protein bcl-2 bcl-xl induc overexpress c-myc recent shown drive apoptosi overexpress sensit cancer cell action proapoptot agent includ 5-fu conclus result indic dha strongli increas antineoplast effect low concentr 5-fu overal result suggest combin low dose two compound repres chemotherapeut approach low toxic
oral bioavail matrix metalloproteinas inhibitor mmi270 reduc tumour growth metastasi preclin model assess feasibl pharmacokinet interact combin mmi270 5-fluorouracil 5-fu folin acid enter studi patient advanc colorect cancer receiv 200 mg/m2 follow 5-fu 400 mg/m2 min 5-fu 600 mg/m2 dai 14-dai cycl mmi270 commenc second cycl onc daili 150 three time daili 300 twice daili dose-limit toxic observ mmi270 dose level ten patient experienc joint symptom independ mmi270 dose lead interrupt modif discontinu treatment seven patient mmi270 alter 5-fu pharmacokinet six patient partial respons seven stabl diseas 5-fu/fa mmi270 dose 300 twice daili well toler mmi270 signific effect 5-fu pharmacokinet
tumor defect dna mismatch repair system msi-h tumor distinct molecular clinicopatholog profil compar mismatch repair-profici tumor associ rel favor prognosi evid suggest colorect cancer patient msi-h tumor respond differ adjuv chemotherapi determin msi statu clinic applic assist diagnosi suspect hereditari nonpolyposi colorect cancer case reason becom increasingli appar test msi conduct routin human cancer type frequent present phenotyp bat-26 bat-25 mononucleotid repeat wide us establish msi statu human tumor show here allel size profil provid estim percentag contamin normal cell msi-h tumor marker sensit enough detect instabl tumor cell content sampl low 5-10 msi-h tumor contain mutat code repeat gene known target instabl case low tumor cell content mutat code repeat detect howev sampl enrich tumor cell mutat detect same target gene bat-26 bat-25 marker accur identifi msi-h tumor prior need enrich tumor cell indic sampl requir purif befor screen mutat target gene instabl result implic larg-scale screen cancer patient determin msi-h statu prognosi
defici costimulatori molecul express implic abil tumor escap immun effector activ intratumor administr recombin fowlpox vector express triad costimulatori molecul rf-tricom evalu asbesto-induc ab12 ac29 mous model mesothelioma mesothelioma cell infect rf-tricom express high level costimulatori molecul prolong surviv observ mice receiv rf-tricom ab12 ac29 intraperiton model complet tumor regress observ mice receiv intratumor rf-tricom ab12 subcutan tumor model tumor regress associ develop serum igg reactiv mesothelioma-associ determin specif system cytolyt activ respond mice capabl reject tumor re-challeng antitumor activ observ mice establish ab12 tumor vaccin irradi rf-tricom-infect ab12 cell antitumor activ intratumor rf-tricom superior intratumor inject fowlpox vector express granulocyt-macrophag coloni stimul factor rf-gm-csf ab12 ac29 tumor found produc gm-csf substanti macrophag infiltr product gm-csf decreas vivo tumor inject rf-tricom rf-tricom wild-type fowlpox inhibit growth ab12 ac29 cell vitro inhibit observ rf-gm-csf result indic intratumor inject rf-tricom signific activ mous model mesothelioma elicit system antitumor immun respons result suggest potenti limit intratumor administr cytokin gm-csf mesothelioma
purpos previous demonstr condit medium bacteria isol colon cancer patient stimul cancer cell invas vitro through 13-mer beta-casein-deriv peptid invas signal pathwai coordin balanc protein kinas phosphatas investig effect condit medium bacteria overal cellular tyrosin phosphoryl method tyrosin phosphoryl level hct-8/e11 human colon cancer cell treat pro-invas condit medium listeria prepar top collagen type gel coll listeria/tsb analys mean immunoprecipit western blot specif anti-phosphotyrosin antibodi result demonstr coll listeria/tsb increas tyrosin phosphoryl level erbb2 erbb3 member epiderm growth factor receptor egfr famili associ erbb3 phosphatidylinositol 3-kinas pi3k regulatori subunit p85alpha coll listeria/tsb-stimul erbb3 tyrosin phosphoryl cancer cell invas independ egfr express activ depend erbb2 activ conclus interact listeria collagen type produc 13-mer peptid least anoth pro-invas factor signal via erbb2/erbb3 heterodim
insulin-like growth factor igf-ii express commonli colorect tumor igf-bind protein-4 igfbp-4 counteract tumor promot activ igf-ii bind growth factor shown previous ls1034 cell highli express igf-ii overexpress igfbp-4 led strong reduct prolifer coloni format invas capac investig effect igfbp-4 molecular level analyz growth paramet ls1034 human colon cancer cell cell express murin igfbp-4 migfbp-4 us subtract cdna librari approach combin cdna arrai hybrid detect chang mrna express profil mrna level sever protein known affect import biolog properti neoplast cell proteolysi prolifer differenti alter overexpress igfbp-4 transcript level tumor marker like carcinoembryon antigen-relat cell adhes molecul ceacam reduc elev migfbp-4 chang mrna level confirm western blot cst1 proteolysi proteas inhibitor cox-2 cell motil ceacam5 tumor marker furthermor effect migfbp-4 apoptosi investig increas apoptosi detect igfbp-4 overexpress ls1034 cell data indic igfbp-4 involv regul gene product known suppos import pathogenesi colon cancer cell
tumor exhibit select allel loss hla class antigen part alter hla phenotyp colorect tumor hla class allel most frequent lost hla-b44 precis mechan respons loss describ date total colorect cryopreserv tumor sampl select immunohistochem stain tumor hla-b44-neg express loss heterozygos 6p21.3 demonstr caus neg express case remain case structur analys microdissect tissu sampl subtyp hla-b44 loss tumor b*4402 b*4403 b*4405 reveal mutat howev subtyp hla-b44 present studi share common characterist presenc aspart amino acid residu posit 114 hla class heavi chain residu describ determin tapasin depend surfac express allel antigen present studi tapasin transcript rt-pcr tumor found tapasin downregul tumor sampl hla-b44-neg phenotyp contrast tapasin normal transcrib hla-b44-posit colorect tumor sampl well hla-b44-neg laryng carcinoma bladder tumor defect tapasin transcript seem alter respons absenc hla-b44 express colorect tumor contribut gener tumor immun escap phenotyp
human colon cancer cell implant subcutan nude mice dai anim divid two group first group receiv microg/kg bodi weight octreotid galanin serotonin via intraperiton implant pump second group receiv steril salin treatment last dai volum weight tumour treat mice tend decreas statist signific prolifer index number tumour blood vessel significantli reduc mice given tripl therapi apoptot index detect tunel method monoclon anti-poli adp-ribos polymeras significantli higher treat mice result investig promis uncertain us present find impli treatment patient colorect cancer
main aim studi evalu clinic relev gelatinas colorect cancer crc nineti-five crc pair normal tissu investig detect total level mmp-9 mmp-2 tissu inhibitor timp-1 timp-2 pro-mmp mmp activ potenti associ clinic paramet estim mmp-9 mmp-2 timp-1 level greater crc normal tissu differ signific mmp-9 timp-1 howev timp-2 show significantli lower level tumour sampl moreov signific differ state activ gelatinas found timp-1 low level significantli associ poor clinic outcom patient accord data differ role attribut mmp-2 mmp-9 crc progress moreov timp-1 level evalu emerg main prognost factor relat gelatinas activ crc
local system immun respons impair patient colorect cancer crc known number tumor infiltr lymphocyt til consider few hand crc case til observ surviv longer case small number til consider attent recent paid relationship chemokin tumor cell chemokin recruit lymphocyt tumor lesion made hypothesi fractalkin cx3c chemokin recruit lymphocyt crc plai import role anti-tumor immun analyz express level fractalkin crc cell line well clinic sampl express level fractalkin found correl densiti til p&lt 0.05 crc case strong fractalkin express show significantli better prognosi weak express p&lt 0.05 addit fractalkin express found independ prognost factor p&lt 0.05 furthermor clarifi tumor-infiltr cell natur killer cell cytotox cell express fractalkin receptor data suggest fractalkin express tumor appear recruit cytotox cell cell tumor site cytotox cell result better prognosi mediat tumor cell cytotox us perforin granzym mechan express level fractalkin essenti biomark predict prognosi patient crc fractalkin consid on biomark detect patient high risk recurr benefit addit therapeut strategi adjuv therapi
mutat p53 common event colorect cancer result cellular accumul p53 protein induct p53 antibodi investig associ colorect cancer alter p53 dna protein serum antibodi level determin prognost valu colorect cancer colorect cancer patient 167 underw surgeri taipei veteran gener hospit januari 1999 decemb 2000 enrol [ag 62.91+/-12.61 year rang 22-85 111 66.5 male] stage stage 32.3 stage iii 34.7 stage median follow-up 36.3 month rang 4-58 p53 alter detect dna sequenc exon loss heterozygos loh two microsatellit marker p53 demonstr intratumor accumul p53 protein detect serum p53 antibodi us elisa p53 mutat frequenc 41.9 70/167 127 inform case loh analysi 57.5 tumor loh least on microsatellit marker genet p53 alter found 56.3 case loh dna sequenc method combin genet p53 alter associ advanc tumor stage tumor differenti overexpress intratumor p53 anti-p53 antibodi posit 44.9 28.1 presenc p53-ab associ p53 mutat chi2 test 42.9 17.5 0.001 overexpress intratumor p53 protein mutat exon 57.1 53.3 associ presenc serum p53-ab 132 potenti cure patient 3-year diseas-free surviv df affect advanc tnm stage iii genet p53 alter intratumor p53 accumul preoper cea level ng/ml multivari analysi genet alter p53 most signific independ prognost factor [hazard ratio 6.09 confid interv 2.45-15.11] follow advanc tumor stage 3.93 2.14-7.23 preoper cea ng/ml 1.98 1.12-3.17 genet alter p53 intratumor p53 protein accumul p53-ab appear plai signific role progress colorect cancer
human malign glioma contain epiderm growth factor receptor egfr gene mutat encod tumor-associ antigen taa target us immunolog techniqu on egfr mutant gene egfrviii encod protein epitop found normal tissu number studi focus uniqu epitop potenti target tumor vaccin present studi examin cellular immun effect peptid contain multipl copi uniqu egfrviii epitop link togeth wai lysin bridg fischer rat vaccin egfrviii multipl antigen peptid map vaccin produc humor immun respons anti-map antibodi product accompani express th2 respons cytokin il-4 map/gm-csf vaccin anim cellular immun respons detect associ appear cd4+ cd8+ cell tumor site splenocyt cd8+ cell vaccin rat produc th1 cytokin ifn-gamma vitro respons stimul rat glioma cell express egfrviii express wild-type egfr map vaccin induc specif lytic antitumor ctl immun respons f98 glioma cell express egfrviii f98 cell express wild-type egfr receptor vivo growth f98 egfrviii cell attenu vaccin rat wherea growth f98 egfr cell median surviv vaccin rat increas unvaccin control challeng intracerebr f98 egfrviii tumor implant map vaccin produc predominantli cellular antitumor immun respons direct f98 glioma express egfrviii target antigen potent immunosuppress effect f98 glioma cell mimic human diseas make particular tumor model us studi immunotherapeut approach malign glioma
selectin famili adhes protein direct leukocyt blood lymphoid organ site inflamm thought involv dissemin carcinoma express sialyl lewi glycan structur sialyl-lewi slex express core beta1 n-acetylglucosaminyltransferas c2gnt leukocyt allow biosynthesi core o-glycan termin slex serv high-affin selectin glycan ligand particular slex-modifi core o-glycan structur c2-o-slex directli demonstr confer significantli higher affin selectin bind slex recent describ reactiv mab cho-131 depend enzym alpha2 3-sialyltransferas alpha1 3-fucosyltransferas c2gnt specif recogn glycan structur c2-o-slex here examin defin pair colon carcinoma cell line distinct capac bind e-selectin demonstr shear flow assai involv whole blood shear stress occur microvasculatur cho-131 demonstr reactiv cancer cell cell line avidli attach e-selectin henc demonstr first time detect c2-o-slex colon carcinoma cell leukocyt directli relev express high affin glycan ligand selectin
epidemiolog studi suggest carotenoid beta-caroten lutein plai import role reduc risk sever cancer howev colon cancer ambigu regard role compound both prevent effect tumor promot observ present studi observ male f344 rat abl toler 500 ppm beta-caroten well lutein assess chemoprevent efficaci beta-caroten lutein dose level approxim 500 ppm toler dose approxim azoxymethan aom -induc colon carcinogenesi us aberr crypt foci acf surrog biomark colon cancer experi 5-week-old male f344 rat fed control diet modifi ain-76a experiment diet contain 100 200 ppm approxim 500 ppm 000 000 ppm approxim 500 ppm beta-caroten lutein rat/group week experiment control diet anim inject aom mg/kg bodi onc weekli week week ag rat kill colon evalu acf administr 100 200 ppm beta-caroten inhibit aom-induc total colon acf format p&lt 0.01 p&lt 0.001 respect wherea lutein 200 ppm produc inhibit p&lt 0.01 yet signific effect 100 ppm dose level surprisingli administr 000 000 ppm beta-caroten lutein increas colon acf format dose-depend manner i.e 124 144 former 110 159 latter result clearli suggest studi warrant determin whether increas acf incid high dose beta-caroten lutein will lead increas tumor outcom taken togeth data indic chemoprevent activ beta-caroten lutein colon carcinogenesi depend dose level
vivo disposit antitumor efficaci newli develop phosphin matrix metalloproteinas inhibitor rxp03 examin rxp03 potent inhibit mmp-11 mmp-8 mmp-13 mmp-1 mmp-7 twenti-four hour i.p inject mice most rxp03 recov intact plasma fece biliari excret tumor tissu pharmacokinet paramet indic i.p dose 100 microg/dai plasma concentr rxp03 remain higher valu determin mmp-11 mmp-8 mmp-13 efficaci rxp03 growth primari tumor induc s.c inject colon carcinoma cell mice observ depend both rxp03 dose treatment schedul tumor volum mice treat dai 100 150 microg/dai rxp03 decreas compar control tumor volum 100 microg/dai most effect dose treatment higher dose 600 microg/dai significantli reduc tumor size compar control short treatment rxp03 100 microg/dai dai inocul effect tumor growth continu treatment dai strikingli rxp03 treatment start dai inject continu dai led stimul tumor growth compar control paradox effect depend rxp03 treatment schedul underlin need defin carefulli spatiotempor function mmp variou stage tumor growth achiev optim therapeut effect mmp inhibitor treatment
consider evid high consumpt red meat increas risk colorect cancer data subsit colon spars object studi prospect examin whether associ red meat consumpt cancer risk vari subsit larg bowel analyz data swedish mammographi cohort 433 women ag 40-75 year free diagnos cancer baselin 1987-1990 diet assess baselin us self-administ food-frequenc questionnair mean follow-up 13.9 year identifi 234 proxim colon cancer 155 distal colon cancer 230 rectal cancer observ signific posit associ red meat consumpt risk distal colon cancer trend 0.001 cancer proxim colon trend 0.95 rectum trend 0.32 multivari rate ratio women consum g/dai red meat compar consum g/dai 2.22 confid interv [ci] 1.34-3.68 distal colon 1.03 0.67-1.60 proxim colon 1.28 0.83-1.98 rectum associ consumpt fish risk cancer subsit poultri consumpt weakli invers relat risk total colorect cancer trend 0.04 find suggest high consumpt red meat substanti increas risk distal colon cancer futur investig red meat colorect cancer risk consid cancer subsit separ
adequ consumpt folat reduc risk colorect cancer perform meta-analysi cohort case-control studi examin associ folat consumpt colorect cancer risk cohort studi associ folat consumpt colorect cancer risk stronger dietari folat folat food alon rel risk high low intak 0.75 0.64-0.89 total folat folat food supplement rel risk high low intak 0.95 0.81-1.11 signific heterogen studi signific heterogen case-control studi result offer support hypothesi folat small protect effect colorect cancer confound dietari factor rule
differenti gene express metastat human colon cancer cell line ht29p nonmetastat counterpart ht29-mtx reveal suppress subtract hybrid fifti-eight individu gene show increas mrna level ht29p cell gene relat transform previou studi major gene candid encod protein relev metastat process cancer profil arrai well situ hybrid studi reveal least gene obtain ssh screen differenti express human tumor
background design dose- time-intensifi high-dose sequenti chemotherapi regimen patient relaps refractori hodgkin lymphoma patient method elig criteria includ ag 18-65 year histolog proven primari progress relaps treatment consist two cycl dhap dexamethason high-dose cytarabin cisplatinum patient chemosensit diseas receiv cyclophosphamid follow peripher blood stem cell harvest methotrex plu vincristin etoposid beam plu peripher blood stem cell transplant pbsct result total 102 patient median ag year rang 18-64 enrol respons rate complet respons partial respons median follow-up month rang 3-61 month freedom second failur ff2f overal surviv patient respect ff2f patient earli relaps late relaps multipl relaps respect multivari analysi respons dhap &lt 0.0001 durat first remiss multipl relaps versu earli late relaps 0.0127 prognost factor ff2f respons dhap &lt 0.0081 durat first remiss 0.0017 anemia 0.019 signific conclus base promis result studi prospect random european intergroup studi start compar intensifi regimen two cours dhap follow beam hd-r2 protocol
order noninvas detect salmonella deliveri vector tumor us genet modifi salmonella vnp20009 express herp simplex thymidin kinas hsv1-tk report gene vnp20009-tk abl select local murin tumor model effect sequest radiolabel nucleosid analogu 2'-fluoro-1-beta-d-arabino-furanosyl-5-iodo-uracil fiau quantit relationship level radioact accumul number bacteria tumor differ tissu demonstr vivo accumul [14c]fiau measur tissu sampl homogen section relat salmonella number immunohistochem bacteri stain respect quantit autoradiographi qar reveal rel intens [14c]fiau accumul tumor cross-section demonstr peripher region tumor significantli activ intern region [124i]fiau positron emiss tomographi pet subsequ tissu radioact bacteri concentr measur compar log-log relationship found pet imag identifi multipl tumor site abil noninvas detect salmonella vector pet imag potenti conduct clinic set aid develop vector demonstr effici durat target well indic locat tumor
role irinotecan-base chemotherapi induct treatment non-resect advanc colorect cancer acrc current elucid object retrospect studi determin complet resect respons rate time progress ttp overal surviv patient non-resect acrc treat neoadjuv irinotecan-base chemotherapi thirti-six patient acrc select treat irinotecan 250 mg/m2 dai uft 300 mg/m2/dai dai plu leucovorin mg/dai dai everi week anoth receiv folfiri schedul irinotecan plu 5-fluorouracil/leucovorin total 214 cycl irinotecan/uft/lv median rang 1-15 cycl folfiri schedul median rang 1-30 administ overal respons rate confid interv 42-74 six complet partial respons wherea seven patient show stabl diseas laparotomi perform patient eight achiev two patholog complet respons median ttp 10.0 month median 38.0 month patient median follow-up month rang 1-49 median ttp patient reach mean ttp 33.1 month wherea median ttp non-resect patient 7.5 month 0.016 toxic manag toxic death occur retrospect studi show high resect rate prolong ttp patient acrc induct treatment irinotecan-base chemotherapi both toxic profil postop complic accept nevertheless definit role irinotecan induct treatment confirm futur clinic trial
efficaci combin therapi irinotecan capecitabin demonstr first-line treatment metastat colorect cancer mcrc aim trial evalu efficaci safeti combin mcrc second-line treatment failur 24-h infusion 5-fluorouracil 5-fu24h folin acid patient pre-treat 5-fu24h/fa recruit two institut receiv weekli irinotecan mg/m2 capecitabin 1000 mg/m2 b.i.d dai 1-14 22-35 cours repeat dai elderli patient year dose reduct both drug schedul twenti-eight patient [m/f 20/8 median ag year rang 44-79 median ecog score enrol most frequent site metastas liver lymph node lung respect half patient two metastat site total treatment cours median rang 1-8 administ main toxic [worst per patient ctc grade 1/2/3/4] anaemia 18/14/-/- leukocytopenia 11/21/-/- thrombocytopenia 11/-/-/- diarrhea 18/36/21/- nausea/vomit 43/29/4/- mucos 4/11/-/- alopecia 7/25/-/- hand-foot syndrom 7/21/-/- fatigu 14/14/-/- renal insuffici caus diarrhea exsiccosi -/-/-/7 dose intens first cours [median/mean irinotecan 92/83 capecitabin 88/82 twenti-three patient evalu respons analysi five complet first cours three patient show partial remiss patient stabl diseas median time progress 3.0 month total popul rang 1.4-17.3 6.5 month respond partial respons plu chang seventi-four percent patient receiv third-line therapi overal surviv 15.7 month calcul start studi treatment second-line therapi irinotecan capecitabin yield tumor control patient mcrc efficaci toxic data compar 5-fu/irinotecan combin likelihood sever diarrhea appear higher capecitabin/irinotecan
alkal intestin tract oral administr sodium bicarbon report promis method prevent delai diarrhea dose-limit toxic patient receiv chemotherapi irinotecan hydrochlorid howev fear method advers affect pharmacokinet irinotecan inhibit intestin absorpt activ metabolit compar pharmacokinet toxic irinotecan oral alkal cross-over studi enrol colorect cancer patient found alkal decreas blood level irinotecan activ metabolit fact area under concentr versu time curv auc irinotecan 7-ethyl-10-hydroxycamptothecin glucuronid sn-38g statist equival both oral alkal auc sn-38 alkal statist equival larger alkal oral alkal reduc incid diarrhea gastrointestin symptom advers effect worsen long-term administr result suggest oral alkal control diarrhea gastrointestin toxic decreas blood level irinotecan activ metabolit improv toler long-term chemotherapi reduc efficaci
object farnesyl diphosph synthas fpp produc fpp consid branch-point intermedi synthesi sterol isoprenyl cellular metabolit studi investig whether detect fpp activ present human colorect cancer crc evalu vitro role enzym growth apoptosi crc cell us pamidron pam fpp activ inhibitor method activ level fpp determin crc normal surround mucosa patient radiochem assai fpp mrna express investig patient quantit revers transcriptas polymeras chain reaction rt-pcr k-ra mutat evalu us pcr restrict enzym analysi cell growth apoptosi pam treatment human crc cell line dld-1 measur mtt test dna fragment respect result fpp activ detect human crc fpp activ mrna significantli abund cancer sampl normal mucosa vitro pam result signific reduct cell growth gave rise mark proapoptot effect conclus studi provid first evid presenc fpp activ human crc moreov fpp enzym found plai signific role colon cancer prolifer
background despit higher rate colorect cancer crc among japanes american littl known risk percept object studi test exploratori model explain psychosoci pathwai perceiv risk crc method postul model test us path analysi data random sampl 306 japanes american ag older result model fit data well chi 10.22 .42 good-of-fit index .993 compar fit index .999 root mean squar approxim .008 cancer fear exert strongest effect perceiv risk follow famili histori conclus risk commun japanes american tailor individu emot pattern associ cancer allevi fear imped accur risk self-assess
late 1970s clinic research investig us platinum compound administ singl agent combin drug treatment varieti cancer includ gastrointestin cancer extens clinic develop oxaliplatin becom import option treatment colorect cancer role treatment gastrointestin cancer cancer remain focu intens investig histor platinum compound shown limit singl-agent activ pancreat cancer recent studi explor potenti synergi us platinum-base combin addit platinum agent long us treatment advanc gastroesophag tumor typic 5-fluorouracil cisplatin combin poor outcom diseas clearli indic need develop activ agent review will examin recent clinic data us platinum-base chemotherapi treatment gastrointestin cancer
avail chemotherapi agent sever year signific impact treatment colorect cancer crc question best us agent remain articl review evid maintain full dose schedul fdo chemotherapi crc date clinic studi focus determin agent combin optim advanc diseas adjuv set combin irinotecan oxaliplatin 5-fluorouracil leucovorin current evalu adjuv treatment crc addit target biolog agent standard chemotherapi regimen evalu treatment advanc diseas few studi investig dose intens adjuv set consequ littl evid link fdo chemotherapi outcom nonetheless benefit maintain fdo chemotherapi shown trial breast cancer non-hodgkin's lymphoma hold true crc furthermor sever studi metastat crc found greater surviv achiev dose-intensifi chemotherapi fdo chemotherapi becom accept treatment crc point overal surviv assess metastat diseas concept will investig adjuv set role fdo chemotherapi crc adequ evalu
cell migrat traffick integr aspect cancer metastasi target develop novel antimetastat therapi tumor cell traffick poorli understood phenomenon due inabl visual process studi visual traffick metastat cell target liver via portal vein us green fluoresc protein gfp -express cancer cell transplant tumor cell ascend colon nude mice metastasi visual vivo singl-cell basi around portal vein gfp imag earli time-point few cell visual traffick liver via portal vein post-implant dai-5 caudat lobe liver involv traffick metastat cell metastasi around portal vein increas rapidli area liver dai-7 post-implant right later lobe liver involv traffick metastat cell dai-9 -11 metastasi increas rapidli around portal vein spread area liver experi demonstr critic role portal vein metastasi liver
infiltr inflammatori cell colorect adenocarcinoma consid import tumour progress tumour-associ macrophag cell predomin compon chemokin-guid filtrat most colorect tumour cxcr6 chemokin receptor express th1 nkt cell smooth muscl cell determin whether cxcr6 express human colorect cancer correspond normal tissu analys cxcr6 protein express surgic specimen immunohistochemistri reveal cxcr6 protein predominantli localis normal epitheli cell scatter stromal cell weak express found cancer tissu western blot analysi show case notabl suppress cxcr6 protein &lt 0.05 cancer tissu compar non-cancer tissu up-regul found case cxcr6 protein express case show differ tumour adjac normal tissu furthermor case reveal undetect level cxcr6 protein tumour well correspond normal tissu result reflect on immunolog featur normal cancer colorect tissu studi regul cxcr6 necessari order determin role colorect carcinogenesi
increas evid accumul support hypothesi growth hormon insulin-like growth factor igf plai role carcinogenesi order test hypothesi femal nude mice xenograft two differ human colorect cancer cell line colo 205 ht-29 random receiv placebo receptor antagonist ghra b2036-peg everi second dai dai tumour volum measur anim studi experi tumour weight record dai therapi nude mice colo 205 colorect cancer ghra treatment caus reduct tumour volum &lt 0.02 reduct tumour weight &lt 0.01 ghra treatment equal reduc circul igf-i igfbp-3 level apoptosi increas treatment group express igf-i igf-ii correspond receptor colo 205 tumour decreas treatment ghra effect growth ht-29 colorect cancer despit pronounc reduct serum igf-i present studi therebi demonstr central role gh/igf system pathogenesi colorect cancer suggest specif ghr blockad present concept treatment colorect cancer
interleukin -23 il-27 recent identifi member il-12 heterodimer cytokin famili cytokin releas activ dentrit cell plai crucial role cell-mediat immun express profil cytokin' receptor suggest target cell cytokin distinct depend cell matur differenti first examin whether murin colon carcinoma cell colon express il-27 colon 26/il-27 produc antitumor effect syngen mice mice develop small colon 26/il-27 tumor subsequ reject wherea parent tumor continu grow colon 26/il-12 colon 26/il-23 cell reject syngen mice investig combinatori antitumor effect cytokin inocul colon 26/il-12 colon 26/il-23 colon 26/il-27 cell mix popul cytokin produc on flank mice simultan receiv parent tumor flank parent tumor growth influenc cytokin produc similar combinatori antitumor effect produc cytokin produc applic cytokin show synergist effect
background evalu hmgcoa reductas activ ldl receptor level human colon cancer well effect simvastatin vitro cell growth apoptosi dld-1 caco2 cell line materi method hmgcoa reductas activ ldl receptor measur radiochem assai elisa method respect cell growth apoptosi evalu mtt-test dna fragment analysi respect result higher hmgcoa reductas activ ldl receptor level detect cancer normal mucosa up-regul hmgcoa reductas activ detect left-side tumor simvastatin treatment produc mark anti-prolif pro-aptot effect dld-1 cell growth inhibit apoptosi evid caco2 cell conclus cholesterol pathwai involv colon malign transform therapeut strategi us hmgcoa reductas inhibitor anti-cancer compound take consider biolog clinic differ detect insid colon tract
background microsatellit instabl msi biolog characterist most tumour involv hereditari non-polyposi colorect cancer hnpcc occur 10-15 sporad colorect cancer crc hnpcc appear caus germlin mutat mismatch repair mmr gene respons repair singl base-pair mismatch msi associ better respons crc adjuv chemotherapi fluoropyrimidin investig relationship msi statu tsmrna express polymorph 5-fluorouracil 5-fu cellular target enzym thymidyl synthas express evalu mean immunohistochemistri materi method seri colorect cancer evalu msi polymorph 3'utr 5'utr gene pcr assai tsmrna quantifi real-time pcr express immunohistochem assai result signific associ polymorph gene msi tsmrna express msi statu crc 3r/3r 2r/3r genotyp show significantli higher tsmrna express 2r/2r genotyp 0.001 0.028 respect anoth signific associ found tsmrna express immunohistochem determin &lt 0.05 associ found polymorph 3'utr tsmrna express conclus data show associ msi statu polymorph utr express tumour sampl displai 3r/3r 2r/3r genotyp higher tsmrna level 2r/2r genotyp polymorph variant 3'utr doe influenc tsmrna level found relationship tsmrna express evalu real-time pcr level determin immunohistochem assai genotyp 5'utr quantif tsmrna express human crc consid predictor respons sfu-base chemotherapi evalu express mean immunohistochemistri assai remain safe reliabl assai crc
background glutathion-s-transferas gst n-acetyltransferas nat involv metabol wide rang carcinogen chemic allel polymorph enzym associ variat enzym activ henc affect concentr activ carcinogen chemic bodi previou studi suggest possibl cancer risk-modifi effect allel polymorph result still controversi evalu effect gstm1 gstt1 gstp1 nat1 nat2 enzym individu suscept colorect cancer particular attent possibl interact studi genotyp materi method five hundr colorect cancer patient 500 match cancer-free control includ studi allel polymorph gstm1 gstt1 gstp1 nat1 nat2 enzym determin pcr-base method peripher blood leukocyt allel distribut compar colorect cancer patient control result gstm1 allel 1.48 1.15-1.92 rapid acetyl genotyp nat2 1.52 1.17-1.98 associ elev risk statist signific correl nat1 gstt1 gstp1 genotyp colorect cancer found remark increas risk associ gstm1 allel--nat2 rapid acetyl genotyp combin 2.39 1.75-3.26 gstm1 allel--nat2 nat1 rapid acetyl tripl combin 3.28 2.06-5.23 carri put high-risk allel substanti increas risk colorect cancer 3.69 2.33-5.86 conclus genotyp certain metabol enzym affect risk colorect cancer effect particularli import certain allel combin studi futur individu level risk assess reach increas number studi polymorph combin tradit epidemiolog risk factor
background preoper diagnosi lymph node metastasi difficult number differ criteria advoc literatur howev optim criterion yet determin patient rectal carcinoma patient method fifti-on patient undergo radic surgeri total mesorect excis examin refer region lymph node statu mri patholog find compar optim preoper criterion clarifi receiv oper characterist roc analysi result among size shape intern structur criteria size signific factor diagnos metastat lymph node mri roc analysi show criterion 6-mm larger longitudin axi most reliabl differenti metastat non-metastat lymph node overal accuraci conclus 6-mm longitudin diamet criterion thought most optim evalu mesorect lymph node statu patient rectal carcinoma
need sensit specif diagnost prognost molecular marker monitor earli pattern gene express non-invas exfoli colonocyt shed stool aggress carcinoma cell blood resect colorect cancer patient rna-base detect method comprehens dna- protein-base method routin systemat abl perform quantit gene express studi non-invas sampl us carefulli select tumor-specif colon cancer gene quantit accur monitor chang variou stage neoplast process allow surgic therapi decreas mortal colorect cancer
background efficaci limit preoper endoscop clip determin resect line patient earli gastric cancer remain unclear materi method subject compris 100 patient earli gastric cancer femal male mean ag 60.5 year rang 33-84 year underw pre-oper endoscop clip lesion locat middl upper corpu stomach result endoscop clip select appropri surgic procedur investig result distal gastrectomi perform patient mean length lesion proxim surgic margin resect stomach 28.9 +/- 18.0 mean +/- surgic margin eventu free tumor patient patient clip consid place inadequ tumor macroscop depress flat size conclus pre-oper endoscop clip repres safe reliabl procedur determin resect line tumor locat middl upper corpu stomach treatment earli gastric cancer surgic resect frozen section examin proxim cut recommend patient tumor macroscop depress flat size displai macroscop unclear proxim margin
vitro gener dendrit cell dc enabl practic antitumor immun therapi peripher monocyt differenti dc presenc granulocyt-macrophag coloni-stimul factor gm-csf interleukin il-4 vitro gener larg number dc compar number dc gener leukapheresi product convent blood sampl healthi volunt induct rate dc equal two blood sampl dc obtain on leukapheresi product contrast number dc vari significantli depend individu 30-50 good respond poor respond dc appear aggreg indent cell cultur good respond larg cell float spars poor respond repeat administr gm-csf il-4 improv yield dc induc prolifer autolog lymphocyt poor respond prototyp cell therapi gener dc will requir titrat differenti process depend individu's respons cytokin
pilot studi effect palli chemotherapi detect rate circul tumour cell peripher venou blood stage colorect cancer patient investig result indic recruit tumour cell chemotherapi suggest poorer surviv tumour cell posit patient circul tumour cell shown potenti prognost factor patient undergo cur resect colorect cancer effect chemotherapi detect rate dissemin tumour cell blood yet adequ investig object pilot-studi analyz circul tumour cell peripher venou blood colorect cancer patient undergo chemotherapi order evalu potenti valu surrog-marker predict clinic outcom chemotherapi hypothesi chemotherapi result reduct detect rate circul tumour cell colorect cancer patient forti-two stage patient examin three differ time point befor palli chemotherapi presenc dissemin tumour cell us previous describ rt-pcr-assai cytokeratin 80.1 patient show dissemin tumour cell least onc befor chemotherapi patient multi-organ metastas posit 62.5 patient local limit diseas 14.3 first chemotherapi detect rate latter group increas 62.5 patient same time 46.3 57.5 clinic therapi respond show increas detect rate 28.5 befor 71.4 chemotherapi contrast chemotherapi effect tumour cell detect rate patient progress diseas befor therapi patient detect circul tumour cell show shorter overal surviv patient circul tumour cell week clinic therapi respond averag live week longer non-respond contrast origin hypothesi data suggest recruit circul tumour cell chemotherapi advanc colorect cancer investig need clarifi potenti role circul tumour cell monitor chemotherapi patient
express tnf ligand malign cell mechan tumour immun escap genet disregul gene code tnf receptor observ neoplast diseas increas number receptor tumour cell ligand-receptor activ caus tumour prolifer metastat potenti structur tnf receptor influenc tnf activ vivo structur tnf gene suggest post-transcript modif base altern splice aim studi analys express gene code tnf receptor r2/r7 exon estim mrna express colorect cancer cell comparison surround tissu free neoplast infiltr search differ splice tnfalphar2/r7 isoform studi includ fifti four patient histopatholog confirm adenocarcinoma stage iii accord ajc tnm classif tissu sampl remov tumour region obtain colorect cancer patient undergo surgic treatment sampl divid two part first on--wa routin examin histopatholog second on--wa us rna extract number tnf receptor mrna copi subsequ quantifi tnf tnfrii gene express estim base number mrna copi microg total rna presenc tnfr2 tnfr2/r7 isoform tumour normal metastat cell observ highest number mrna tnf copi express tnf gene investig significantli notic metastat cell lymph node decreas number tnfr2/r7 mrna copi metastat lymph node secondarili influenc decreas tnf solubl receptor' concentr conclus genet disregul observ neoplast diseas usual concern dysfunct cytokin receptor gene
purpos studi report here evalu potenti impact tension pelvic muscl set-up error twenti-nine consecut patient rectal cancer includ treatment simul later beam prone posit perform twice-with relax maxim tens pelvic muscl second simul couch move align centr beam actual posit skin mark tattoo first simul boni landmark both imag correspond later field match beam's centr displac rotat measur us beam imag taken relax posit refer absolut valu us calcul mean anterior-posterior direct mean valu displac 15.3 standard deviat 6.9 maxim valu cranial-caudal direct mean valu 4.4 maxim valu mean rotat pelvi 5.3 degre 2.4 degre maxim rotat degre major displac posterior caudal direct major rotat clockwis shown pelvic muscl tension reason anal verg displac misposit shield block result set-up inaccuraci especi anterior-posterior direct shield block misposit anal verg displac
colorect cancer on lead caus cancer-relat death worldwid intrins well acquir resist chemotherapi remain major problem treatment diseas great import develop patient-tailor treatment strategi colorect cancer patient tumor necrosi factor-relat apoptosi-induc ligand trail act through pro-apoptot dr4 dr5 receptor tumor cell harm normal cell will soon test clinic trial novel anti-cancer agent howev human colon cancer cell line sensit trail due intrins acquir trail-resist review discuss mechan modul trail-resist colon cancer cell cell sensit trail affect trail-receptor express cell membran dr4/dr5 ratio function trail-receptor addit intracellular factor lead trail-resist affect caspas 8/c-flip ratio loss caspas caspas due mutat gene methyl carp-depend degrad activ caspas chang caspas c-flip express level downstream trail apoptot pathwai bax mutat increas express iap famili member particularli xiap survivin caus resist chemotherapeut drug nsaid interferon-gamma proteasom inhibitor overcom trail-resist act trail-receptor express chang express pro- anti-apoptot protein
tumor suppressor p53 induc apoptosi through transactiv target gene previou work shown p53-depend gene express chang respons ioniz radiat tissu specif determin critic p53 target gene colon irradi wild-type p53-null mice examin global p53 gene express pattern respons ioniz radiat microarrai analysi us affymetrix moe430a genechip show gene increas p53-depend manner serin proteas e.g elastas trypsin proteas e.g carboxypeptidas revers transcript polymeras chain reaction rt-pcr immunohistochemistri western blot us valid microarrai result trypsin carboxypeptidas elastas-2 three gene potenti p53-bind element studi tissu specif mediat p53-depend respons serin proteas will greatli increas understand vivo p53-depend pathwai colon trigger ioniz radiat
convent therapi local advanc rectal cancer involv surgeri adjuv therapi standard adjuv therapi combin modal treatment includ 5-fluorouracil chemotherapi radiat standard care term time adjuv therapi whether pre- postop continu evolv potenti advantag disadvantag exist both neoadjuv adjuv combin modal therapi newer modal assess endoscop ultrasound impact accur stage local advanc rectal cancer impact choic therapi continu emphasi improv surviv decreas local recurr minim treatment toxic improv qualiti life goal ongo research field rectal cancer
purpos purpos studi determin whether type oper sphincter spare procedur ssp abdomino-perin resect apr primari adenocarcinoma rectum periton reflect affect surviv recurr cur surgeri materi method prospect control studi seventi nine patient low rectal carcinoma done januari 1999 march 2003 two type oper done ssp patient includ low anterior resect doubl-stapl techniqu dst hand-sewn colorect anastomosi hsa apr patient outcom factor evalu oper time intraop blood loss mortal morbid diseas-free surviv tumor recurr patient follow-up minimum month mean time month result patient underw ssp on mortal morbid anastomot leakag occur case on patient need colostomi apr group mortal morbid found morbid similar both group local recurr rate ssp apr 13.8 22.2 respect 0.540 distant metastas rate 11.1 8.3 respect 1.000 two-year diseas-free surviv rate ssp apr patient 73.3 66.7 respect 0.121 intraop blood loss significantli lower ssp group conclus sphincter save procedur perform patient rectal carcinoma regardless site lesion long distal later margin clear surviv risk local recurr similar obtain standard abdomino-perin resect unlik abdomino-perin resect sphincter save procedur preserv contin give accept good qualiti life
